NEW YORK (GenomeWeb News) – Empiriko will use Interchim's mass spectrometry-based technology to perform drug metabolism studies as part of a partnership between the companies announced today.

Under the terms of the deal, Empiriko will leverage Interchim's PuriFlash MassSpec technology to perform near real-time and cost-effective in vitro and ex vivo studies using Empiriko's Biomimiks technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: Leukemia-like disease in soft-shell clams, mNET-seq method for profiling growing transcripts, and more.

While James Watson and Francis Crick are credited for discovering the structure of DNA, Rich proved their theory of a double helix structure was correct when he produced a distinct image of the structure.

Nature News reports that early users of Oxford Nanopore's hand-held MinIon are giddy about the technology and its uses. 

According to MIT Technology Review, Apple is collaborating with researchers to develop apps for consumer DNA testing.